All In Biotech

Drug Trial Radar · NCT02536755

Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies

Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies

Last checked: Nov 19, 2026Latest source record: Jul 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

31

Actual

Start

Oct 27, 2015

Primary completion

Jun 24, 2021

Study completion Jun 24, 2021

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Evaluate long term skeletal response to eliglustat in adult participants who successfully completed one of the Phase 2 or Phase 3 eliglustat studies. Secondary Objective: Evaluate the safety of eliglustat (by serious adverse event continuous monitoring), the quality of life (Short Form-36 Health Survey \[SF-36\]) and biomarkers of Gaucher disease type 1 (GD1) (chitotriosidase, plasma glucosylceramide \[GL-1\] and lyso glucosylceramide \[lyso-GL-1\]) in adult participants who successfully completed one of the Phase 2 or Phase 3 studies.

Conditions

  • Gaucher Disease

Interventions

  • Eliglustat, GZ385660Drug

    Pharmaceutical form: capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Mobility Status Assessments at Study Baseline, Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  2. Number of Participants With Bone Pain Levels During the Past 4 Weeks at Study Baseline, Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  3. Number of Participants With Bone Crisis at Study Baseline, Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  4. Change From Current Study Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  5. Change From Eliglustat Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
  6. Change From Current Study Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  7. Change From Eliglustat Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
  8. Change From Current Study Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  9. Change From Eliglustat Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
  10. Change From Current Study Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  11. Change From Eliglustat Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208Time frame: Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
  12. Total Number of New or Worsening Osteonecrosis Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  13. Total Number of New or Worsening Fracture Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  14. Total Number of New or Worsening Infarcts Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208Time frame: Study Baseline, Weeks 52, 104, 156 and 208
  15. Total Number of New or Worsening Lytic Lesions Events for Spine at Study Baseline, Week 104, and 208Time frame: Study Baseline, Weeks 104, and 208
  16. Observed Annual Incidence Rate for Spine and Femur Osteonecrosis at Week 52, 104, 156 and 208Time frame: For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
  17. Observed Annual Incidence Rate for Spine and Femur Fracture at Week 52, 104, 156 and 208Time frame: For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
  18. Observed Annual Incidence Rate for Spine and Femur Infarcts at Week 52, 104, 156 and 208Time frame: For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
  19. Observed Annual Incidence Rate for Spine Lytic Lesion at Week 104, and 208Time frame: For 104 Weeks (i.e., 2 year), and 208 Weeks (i.e., 4 years)
  20. Change From Current Study Baseline in Bone Biomarker Level: Macrophage Inflammatory Protein 1 Beta (MIP-1β) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Study Baseline, Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234
  21. Change From Eliglustat Baseline in Bone Biomarker Level: Macrophage Inflammatory Protein 1 Beta (MIP-1β) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
  22. Change From Current Study Baseline in Bone Biomarker Level: Procollagen 1 N- Terminal Propeptide (P1NP) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Study Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
  23. Change From Eliglustat Baseline in Bone Biomarker Level: Procollagen 1 N- Terminal Propeptide (P1NP) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
  24. Change From Current Study Baseline in Bone Biomarker Level: Type 1 Collagen C-Telopeptides (CTx) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Study Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
  25. Change From Eliglustat Baseline in Bone Biomarker Level: Type 1 Collagen C-Telopeptides (CTx) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234Time frame: Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 124002

    Montreal, Canada

  • Investigational Site Number 643001

    Moscow, Russia

  • Investigational Site Number 643002

    Saint Petersburg, Russia

  • Investigational Site Number 788001

    Tunis, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.